In the absence of ADAMTS14, fibulin 2 levels are increased, and fibulin 2 in turn outcompetes latent TGFβ for binding to Fibrillin, facilitating the release of active TGFβ into the tumour milieu (Figure 6G). Here, FBLN2 is linked to neoplasm.